- Milestone Scientific has a platform technology for the safe delivery of injections, with one application already commercialized and another one (the CompuFlo) close.
- The health and cost benefits of the CompuFlo are clear, and there is an obvious and large market with 11 million epidurals per year in the US alone.
- There has been a delay in the commercialization process, and the company’s dental business is suffering, hence the extreme share price volatility.
- With a new financing and restrictions on dental practices easing, better times might lay ahead, but this is only for the risk-tolerant investor.
Milestone Scientific Surges Again
April 30th, 2020 · No Comments